Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

By Ross L. Levine, A. Pardanani, A. Tefferi, D. Gilliland. Nature Reviews. Cancer, 2007

600 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1e637b0020aaf56cf65512197f32e0aa6b444c30

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. O’Shea

In Molecular Biology

1. B. Schulman
2. J. O’Shea

Citations in the corpus

• Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) (2011, background): “The vital role of JAK signaling is illustrated best by the circumstances where these kinases are mutated or deleted (5, 6).”
• JAK mutations in high-risk childhood acute lymphoblastic leukemia (2009, background): “It has been hypothesized that the nature of the JAK mutation plays a direct role in establishing the disease phenotype (9, 23, 24), and mutations at R683 have been identified almost exclusively in DS-ALL-related ALL (10, 11).”